SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-15-410880
Filing Date
2015-12-22
Accepted
2015-12-22 16:39:05
Documents
1
Group Members
BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.BAY CITY CAPITAL LLCBAY CITY CAPITAL MANAGEMENT V LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 TO SCHEDULE 13D d102568dsc13da.htm SC 13D/A 97412
  Complete submission text file 0001193125-15-410880.txt   99240
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Subject) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-81034 | Film No.: 151302566
SIC: 2834 Pharmaceutical Preparations

Mailing Address 750 Battery Street Suite 400 San Francisco CA 94111
Business Address 750 Battery Street Suite 400 San Francisco CA 94111 415-676-3830
Bay City Capital Fund V, L.P. (Filed by) CIK: 0001401826 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A